RxDoctor Payments DataLook up a doctor →

Adam Berlinberg, MD

Rheumatology · Denver, CONPI 1255728085

Payments from drug & device makers

$94,287in general payments, 2019–2025

Across 430 payments — averaging $219.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$85K
  • GSK$4K
  • Johnson & Johnson$1K
  • AbbVie$937
  • Pfizer$502
  • AstraZeneca$391
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$1,4001%
  • Speaking & faculty fees$76,00081%
  • Travel & lodging$8,3019%
  • Food & beverage$8,5469%
  • Education$400%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,287 in reported general payments places this provider in the 85th percentile of 108 rheumatology providers in Colorado.

See all rheumatology providers in Colorado

Medicare billing

Part B allowed, 2024
$2,180,389
Medicare patients
488
Services billed
101,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept21$163,490
Humira(Cf)Adalimumab13$104,524
OtezlaApremilast16$91,268
ForteoTeriparatide11$47,189
Colchicine16$5,728
Hydroxychloroquine Sulfate97$3,875
MethotrexateMethotrexate Sodium129$3,788
Leflunomide34$2,926
Prednisone219$1,908
Celecoxib54$1,479
Allopurinol95$1,084
Mycophenolic AcidMycophenolate Sodium12$834
Tramadol Hcl51$786
Sulfasalazine19$667
Gabapentin23$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$937$104,52413 claims
AmgenOtezla$84,546$91,26816 claims
Lilly USA, LLCForteo$81$47,18911 claims
Scilex Pharmaceuticals Inc.Colchicine$15$5,72816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 108 rheumatology providers in Colorado.

Other rheumatology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →